Skip to content
CVE Ledger
  • Newest CVEsPage
  • Recently added to KEVPage
  • Rising exploitation (EPSS)Page
  • Weekly digestPage
  • StatisticsPage
  • WatchlistPage
  • API docsPage
  • MCP serverPage
  • AboutPage
  • Data sourcesPage
  • Data statusPage
  • ChangelogPage
  • How it's builtPage
  • Support the projectPage

14 results

Back

CVE-2020-10627Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an…

Description

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Timeline

  1. ID reserved

    By icscert

  2. · 21 months later

    Published

  3. · 3 years later

    Record updated

Changes after publication (a new score, a public exploit, EPSS crossing 1, 10 or 50 %, leaving KEV) are kept since November 2026; earlier ones are not known.

Scores

CVSS scores of CVE-2020-10627, by who scored it
Scored byCVSSScoreVector
icscertCNA (assigner)3.1High7.3CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:L
NVDNVD · Modified3.1High8.1CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
EPSS (exploitation in 30 days)
0.49% · top 57% of all CVEs (19 Nov 2026)
Loading the EPSS history…

The list uses the assigner's score when there is one, then CISA's, then NVD's: High 7.3.

Affected products

What to do

Workaround: Insulet recommends patients using the affected products talk to their healthcare provider about the risks of continued use, including the possibility of changing to the latest model with increased cybersecurity protection. Additionally, Insulet recommends all patients take the cybersecurity precautions indicated below. Do not connect to or allow any third-party devices to be connected to or use any software not authorized by Insulet. Maintain tight physical control of the pump and devices connected to the pump. Be attentive to pump notifications, alarms, and alerts. Immediately cancel any unintended boluses (a single dose of insulin administered all at once). Monitor blood glucose levels closely and act as appropriate. Get medical help immediately when experiencing symptoms of severe hypoglycemia or diabetic ketoacidosis or if you suspect insulin pump settings or insulin delivery has changed unexpectedly. Insulet has released additional patient-focused information: https://www.myomnipod.com/security-bulletins More information is available regarding Insulet’s product security and vulnerability management: https://www.myomnipod.com/product-security

References

References2

Sources

The same CVE in the primary databases and aggregators, to check against.

Badge for a README or a ticket

CVE-2020-10627 badge
[![CVE-2020-10627](https://cveledger.app/badge/CVE-2020-10627.svg)](https://cveledger.app/cve/CVE-2020-10627)

Record last updated .